Literature DB >> 21251614

Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.

Michel DuPage1, Ann F Cheung, Claire Mazumdar, Monte M Winslow, Roderick Bronson, Leah M Schmidt, Denise Crowley, Jianzhu Chen, Tyler Jacks.   

Abstract

Neoantigens derived from somatic mutations in tumors may provide a critical link between the adaptive immune system and cancer. Here, we describe a system to introduce exogenous antigens into genetically engineered mouse lung cancers to mimic tumor neoantigens. We show that endogenous T cells respond to and infiltrate tumors, significantly delaying malignant progression. Despite continued antigen expression, T cell infiltration does not persist and tumors ultimately escape immune attack. Transplantation of cell lines derived from these lung tumors or prophylactic vaccination against the autochthonous tumors, however, results in rapid tumor eradication or selection of tumors that lose antigen expression. These results provide insight into the dynamic nature of the immune response to naturally arising tumors. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21251614      PMCID: PMC3069809          DOI: 10.1016/j.ccr.2010.11.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  52 in total

Review 1.  A listing of human tumor antigens recognized by T cells: March 2004 update.

Authors:  Luisa Novellino; Chiara Castelli; Giorgio Parmiani
Journal:  Cancer Immunol Immunother       Date:  2004-08-07       Impact factor: 6.968

2.  High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.

Authors:  Sytse J Piersma; Ekaterina S Jordanova; Mariëtte I E van Poelgeest; Kitty M C Kwappenberg; Jeanette M van der Hulst; Jan W Drijfhout; Cornelis J M Melief; Gemma G Kenter; Gert Jan Fleuren; Rienk Offringa; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

3.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

Authors:  H L Hanson; D L Donermeyer; H Ikeda; J M White; V Shankaran; L J Old; H Shiku; R D Schreiber; P M Allen
Journal:  Immunity       Date:  2000-08       Impact factor: 31.745

4.  TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis.

Authors:  Nele Müller-Hermelink; Heidi Braumüller; Bernd Pichler; Thomas Wieder; Reinhard Mailhammer; Katrin Schaak; Kamran Ghoreschi; Amir Yazdi; Roland Haubner; Christian A Sander; Ralph Mocikat; Markus Schwaiger; Irmgard Förster; Ralph Huss; Wolfgang A Weber; Manfred Kneilling; Martin Röcken
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

5.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

6.  High antigen levels are the cause of T cell exhaustion during chronic viral infection.

Authors:  Scott N Mueller; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

7.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Authors:  Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes.

Authors:  Peter A Savage; Keith Vosseller; Chulho Kang; Kevin Larimore; Elyn Riedel; Kathleen Wojnoonski; Achim A Jungbluth; James P Allison
Journal:  Science       Date:  2008-01-11       Impact factor: 47.728

9.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

10.  Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.

Authors:  Linh T Nguyen; Alisha R Elford; Kiichi Murakami; Kristine M Garza; Stephen P Schoenberger; Bernhard Odermatt; Daniel E Speiser; Pamela S Ohashi
Journal:  J Exp Med       Date:  2002-02-18       Impact factor: 14.307

View more
  117 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 2.  Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation.

Authors:  Jatin Roper; Tuomas Tammela; Adam Akkad; Mohammad Almeqdadi; Sebastian B Santos; Tyler Jacks; Ömer H Yilmaz
Journal:  Nat Protoc       Date:  2018-01-04       Impact factor: 13.491

Review 4.  Phenotype, development, and biological function of myeloid-derived suppressor cells.

Authors:  Yang Zhao; Tingting Wu; Steven Shao; Bingyi Shi; Yong Zhao
Journal:  Oncoimmunology       Date:  2015-10-14       Impact factor: 8.110

5.  An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression.

Authors:  Miriam Walter; Elina Simanovich; Vera Brod; Nitza Lahat; Haim Bitterman; Michal A Rahat
Journal:  Oncoimmunology       Date:  2015-08-28       Impact factor: 8.110

Review 6.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.

Authors:  James N Arnold; Lukasz Magiera; Matthew Kraman; Douglas T Fearon
Journal:  Cancer Immunol Res       Date:  2013-11-18       Impact factor: 11.151

8.  Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Authors:  Ingunn M Stromnes; J Scott Brockenbrough; Kamel Izeradjene; Markus A Carlson; Carlos Cuevas; Randi M Simmons; Philip D Greenberg; Sunil R Hingorani
Journal:  Gut       Date:  2014-02-20       Impact factor: 23.059

9.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

10.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.